Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Chief R&D Officer | February 15, 2022 | September 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date February 15, 2022 · Filed September 01, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,463 |
Reported balance
Holding disclosure · report date 2022-02-15 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 94,463 F1: On February 17, 2022, the reporting person filed a Form 4 which inadvertently reported an incorrect number of shares owned. This amendment is filed solely to correct the number of shares owned. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 17, 2022, the reporting person filed a Form 4 which inadvertently reported an incorrect number of shares owned. This amendment is filed solely to correct the number of shares owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 23:23 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001209191-22-010982 · doc4.xml · derivative · entry 2 Pierce Robert Hamilton · CIK 0001594129 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-14 F2 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:23 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010982 · doc4.xml · nonDerivative · entry 1 Pierce Robert Hamilton · CIK 0001594129 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 21:07 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 16,030 | $7.34 | $117,717.91 |
DisclosureSEC source: 0001209191-21-051172 · doc4.xml · nonDerivative · entry 1 Pierce Robert Hamilton · CIK 0001594129 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $7.81, inclusive. The reporting person undertakes to provide to Sensei Biotherapeutics, Inc., any security holder of Sensei Biotherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:40 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 66,350 | $7.13 | $473,002.52 |
DisclosureSEC source: 0001209191-21-050659 · doc4.xml · nonDerivative · entry 3 Pierce Robert Hamilton · CIK 0001594129 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 16,030 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.42, inclusive. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:40 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 6,982 | $7.06 | $49,295.01 |
DisclosureSEC source: 0001209191-21-050659 · doc4.xml · nonDerivative · entry 2 Pierce Robert Hamilton · CIK 0001594129 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 82,380 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.10, inclusive. F2 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:40 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | SaleCommon Stock | 6,460 | $7.11 | $45,948.04 |
DisclosureSEC source: 0001209191-21-050659 · doc4.xml · nonDerivative · entry 1 Pierce Robert Hamilton · CIK 0001594129 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 89,362 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.20, inclusive. The reporting person undertakes to provide to Sensei Biotherapeutics, Inc., any security holder of Sensei Biotherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4. F2 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.